Corneal Versus Conjunctival Delivery Using a Delivery Device

Phase 2WithdrawnNCT00143429

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Overview

Compare the antihypertensive efficacy of three methods for installing Xalatan

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

XalatanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes Exclusion Criteria: * History of closed/barely open anterior chamber angle or a history of angle closure

Outcomes

Primary Outcomes

IOP level in the study eye

Secondary Outcomes

Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.